Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice
Analytical Cellular Pathology · 2018 · 2018 · 1-12
DOI: 10.1155/2018/3506874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Cellular Pathology, 2018. Verfasst von Annalisa Milano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Clinical Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Practice Patterns, Physicians'. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Fondazione AIOM.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related mortality; nevertheless, there are few data regarding detection of circulating tumor cells (CTCs) in NSCLC, compared to other kinds of cancers in which their prognostic roles have already been defined. This difference is likely due to detection methods based on the epithelial marker expression which ignore CTCs undergoing epithelial-mesenchymal transition (CTCs EMT ).
Methods
After optimization of the test with spiking experiments of A549 cells undergoing TGF- β 1-induced EMT (A549 EMT ), the CTCs EMT were enriched by immunomagnetic depletion of leukocytes and then characterized by a RT-PCR assay based on the retrieval of epithelial and EMT-related genes. Blood samples from ten metastatic NSCLC patients before starting treatment and during chemotherapy were used to test this approach by longitudinal monitoring. Ten age- and sex-matched healthy subjects were also enrolled as controls.
Results
Recovery experiments of spiked A549 EMT cells showed that the RT-PCR assay is a reliable method for detection of CTCs EMT . CTCs EMT were detected in three patients at baseline and in six patients after four cycles of cysplatin-based chemotherapy. Longitudinal monitoring of three patients showed that the CTCs EMT detection is related to poor therapeutic response.
Conclusions
The RT-PCR-based approach for the evaluation of CTCs EMT phenotype could be a promising and inexpensive tool to predict the prognosis and the therapeutic response in NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Clinical Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.
- Oncology Unit, Sant'Andrea University Hospital, Rome, Italy.
- Cellular Diagnostics Unit, Sant'Andrea University Hospital, Rome, Italy.
ORCID-Profile: Concetta Elisa Onesti, Salvatore Raffa
Förderung
- Boehringer Ingelheim
- Fondazione AIOM
Zitieren
APA
Milano, A., Mazzetta, F., Valente, S., Ranieri, D., Leone, L., Botticelli, A., Onesti, C. E., Lauro, S., Raffa, S., Torrisi, M. R., & Marchetti, P. (2018). Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Analytical Cellular Pathology, 2018, 1-12. https://doi.org/10.1155/2018/3506874
Vancouver
Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A, et al. Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Analytical Cellular Pathology. 2018;2018:1-12. doi:10.1155/2018/3506874
BibTeX
@article{Milano2018,
author = {Milano, Annalisa and Mazzetta, Francesca and Valente, Sabatino and Ranieri, Danilo and Leone, Laura and Botticelli, Andrea and Onesti, Concetta Elisa and Lauro, Salvatore and Raffa, Salvatore and Torrisi, Maria Rosaria and Marchetti, Paolo},
title = {Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice},
journal = {Analytical Cellular Pathology},
year = {2018},
volume = {2018},
pages = {1--12},
doi = {10.1155/2018/3506874}
}
EUVIMED